Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.17 (
CaMKII
)
4,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to explore the mechanism underlying the antidepression activity of paeoniflorin, the main active ingredient of paeony extract and Shuyu capsules, and determine its effect on the calmodulin/calmodulin-dependent protein kinase II (CaM/
CaMKII
) signalling pathway and on the possible target, the voltage-gated calcium channel (Ca
v
). Rats at the nonacceptance stage were selected for
premenstrual syndrome
(
PMS
) depression modelling. Behavioural assays were used for model testing. Rats were given Shuyu capsules, paeony extract, and bupleurum. Western blot analysis was used to assess the expression levels of calcium voltage-gated channel subunit alpha 1 C (CACNA1C), brain-derived neurotrophic factor, and CaM/
CaMKII
signalling pathway proteins. Intracellular Ca
2+
concentration in CHO cell line was measured using Fluo-4-AM and whole-cell patch clamps. The
PMS
depression model was successfully established and demonstrated that Shuyu can mitigate depressive behaviour in a rat
PMS
model. Paeony extract did not affect CACNA1C protein expression in rat hippocampi but did affect Ca
v
1.2-mediated CaM/
CaMKII
signalling pathways. Paeoniflorin significantly inhibited KCl-induced increases in intracellular Ca
2+
concentration and Ca
v
1.2 current density. Further, it may function via the CaM/
CaMKII
pathway and its downstream signalling molecules by regulating Ca
v
1.2, thus playing an important role in the treatment and alleviation of affective disorders.
...
PMID:Paeoniflorin, the Main Active Ingredient of Shuyu Capsule, Inhibits Ca
v
1.2 and Regulates Calmodulin/Calmodulin-Dependent Protein Kinase II Signalling. 2936 18
